Recent News

• 03.12.2026 - Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
• 02.20.2026 - Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
• 02.12.2026 - Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
• 01.28.2026 - Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

Recent Filings

• 03.11.2026 - 8-K Current report
• 03.11.2026 - EX-99.1 EX-99.1
• 03.09.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.09.2026 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 03.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.05.2026 - S-3MEF Registration adding securities to prior Form S-3 registration [Rule 462(b)]
• 02.10.2026 - EX-99.1 EX-99.1
• 02.10.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2026 - 8-K Current report
• 02.04.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors